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background:  The use of the new antiplatelets in patients undergoing percutaneous coronary intervention (PCI) has been associated with 
decreased major adverse cardiac events (MACE) when compared to clopidogrel but with an increased risk of major bleeding (MB). However, it 
remains unclear if the risks of MB outweigh those of MACE in patients on new antiplatelet therapy.
methods: We searched PubMed, CENTRAL, EMBASE, CINAHL, EBSCO, and Web of Science databases for randomized controlled trials (RCTs) of new 
antiplatelets in patients undergoing PCI, and reporting on both MACE and MB. We defined MACE as a composite outcome of cardiovascular deaths, 
myocardial infarction, stent thrombosis and target vessel revascularization. Major bleeding was defined according to the Thrombolysis in Myocardial 
Infarction (TIMI) criteria. A comparative estimate was made for the combined rates of MACE and MB from the same trials in the framework of a 
meta-analysis, and expressed as odds ratios (ORs) and 95% confidence intervals in both fixed and random effects models.
results: 36037 patients from 12 RCTs were included in this analysis. New antiplatelets include Prasugrel, Ticagrelor, Cangrelor, Elinogrel and 
Vorapaxar. In both the random and fixed effects models, the risk of MACE outweighed that of MB [OR 10.30 (6.44-16.46), p<0.00001-random 
effects].
Conclusion: Despite the increased risk of bleeding associated with the new antiplatelets compared to Clopidogrel, the risk of MACE far outweighed 
the risk of major bleeding.
